araag2/HINT huggingface dataset:
Clinical trial NCT00350051 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: sagopilone (zk 219477) + prednisone
SMILES: C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Must have evidence of confirmed metastatic prostate cancer

          -  Serum testosterone must be less than 50 ng/mL

          -  Disease must be progressing despite anti-androgen therapy

          -  PSA level must be elevated

          -  Additional criteria determined at screening visit

        Exclusion Criteria:

          -  Any previous cytotoxic chemotherapy for prostate cancer

          -  Use of any investigational drug in the last 4 weeks

          -  Symptomatic brain tumors requiring radiation to the brain

          -  Active infection

          -  Additional criteria determined at screening visit
Clinical trial NCT00458913 (phase 2, status: completed)
Conditions: malignant mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: bortezomib, cisplatin
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed pleural malignant mesothelioma, meeting 1 of the following
             criteria:

               -  Recurrent disease after radical surgery

               -  Disease not considered suitable for radical treatment

          -  Measurable or evaluable disease

          -  No clinical evidence of brain or leptomeningeal metastases

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Life expectancy > 12 weeks

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Absolute neutrophil count > 1,500/mm³

          -  Platelet count > 100,000/mm³

          -  Creatinine clearance > 60 mL/min OR > 50 mL/min

          -  ALT and AST < 2.5 times upper limit of normal (ULN) (< 5 times ULN if liver metastases
             present)

          -  Bilirubin < 1.5 times ULN

          -  No concurrent secondary malignancy except carcinoma in situ of the cervix or
             adequately treated basal cell skin cancer

          -  No other malignancy treated within the past 5 years

               -  Melanoma, breast cancer, or hypernephroma treated within the past 5 years and
                  without recurrence are allowed

          -  No uncontrolled or severe cardiovascular disease, including any of the following:

               -  Myocardial infarction within the past 6 months

               -  New York Heart Association class III-IV heart failure

               -  Uncontrolled angina

               -  Clinically significant pericardial disease or cardiac amyloidosis

          -  No infiltrative pulmonary or pericardial disease

          -  No preexisting peripheral neuropathy

          -  No known or suspected allergy or intolerance to boron, mannitol, or heparin, if an
             indwelling catheter is used

          -  No psychological, familial, sociological, or geographical condition that would
             preclude protocol compliance

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior systemic chemotherapy for mesothelioma

          -  No other concurrent antineoplastic agents except medications that may have
             antineoplastic activity but are taken for other reasons (e.g., megestrol acetate,
             cyclooxygenase-2 inhibitors, or bisphosphonates)

          -  No other concurrent experimental agents
Clinical trial NCT00145418 (phase 2, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: oxaliplatin + docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC)

          -  Patients must have measurable disease

          -  Age greater than or equal to 18 years

          -  ECOG performance score of 0, 1, or 2

          -  Absolute neutrophil count (ANC) > 1,500

          -  Platelets > 100,000

          -  Serum creatinine < 1.5mg/dL

          -  Serum total bilirubin < 1.5mg/dL

          -  Alkaline phosphatase < 3 times the upper limit of normal

          -  SGOT/SGPT < 3 times the upper limit of normal

          -  Patients must be recovered from the effects of any prior surgery or RT.

          -  Patients or their legal representatives must be able to read, understand and provide
             informed consent to participate in the trial.

          -  Patients of childbearing potential and their partners must agree to use an effective
             form of contraception during the study and for 90 days following the last dose of
             study medications.

        Exclusion Criteria:

          -  Patients with an active infection > 38.5 degrees Celsius within 3 days of the first
             scheduled day of protocol treatment

          -  Patients with active central nervous system (CNS) metastasis. Patients with stable CNS
             disease, who have undergone radiotherapy at least 4 weeks prior to the planned first
             protocol treatment and who have been on a stable dose of corticosteroids for 2 weeks
             are eligible for the trial.

          -  History of prior malignancy within the past 5 years except for curatively treated
             basal cell carcinoma of the skin; cervical intra-epithelial neoplasm, or localized
             prostate cancer with a current prostate specific antigen (PSA) of < 1.0 mg/dL

          -  Patients with known hypersensitivity to any of the components of oxaliplatin or
             docetaxel

          -  Patients who have had prior chemotherapy for lung cancer

          -  Patients who are receiving concurrent investigational therapy or who have received
             investigational therapy within 30 days of the first scheduled day of protocol
             treatment

          -  Grade 2 peripheral neuropathy

          -  Patients who are pregnant or lactating

          -  Any other medical condition, including mental illness or substance abuse deemed by the
             investigator to be likely to interfere with the patients' ability to sign informed
             consent, cooperate and participate in the study, or interfere with the interpretation
             of the results

          -  History of allogeneic transplant

          -  Known HIV, hepatitis B or C (active, previously treated, or both)
Clinical trial NCT00198055 (phase 2, status: completed)
Conditions: asperger's disorder, pervasive developmental disorder
ICD codes: F84.5
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Mental age of 18 months

          -  Diagnosis of Asperger's Disorder or Pervasive Developmental Disorder

          -  Good health overall

          -  Free of all psychotropic medication for 2 weeks

        Exclusion Criteria:

          -  Weight less than 15kg

          -  Subjects who have received an adequate trial of aripiprazole

          -  An active seizure disorder

          -  A significant medical condition

          -  History of neuroleptic malignant syndrome

          -  Females with positive Beta human chorionic gonadotropin(HCG) pregnancy test
Clinical trial NCT01438827 (phase 2/phase 3, status: completed)
Conditions: allergic rhinoconjunctivitis
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: avanz phleum pratense, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A history of grass pollen allergy

          -  Positive skin prick test to grass

          -  Positive Immunoglobulin E test to grass

        Exclusion Criteria:

          -  Other allergies overlapping the grass pollen season

          -  Severe Asthma (defined as a Forced expiratory volume in 1 second (FEV1) below 70 %
             after adequate treatment)
Clinical trial NCT00653939 (phase 2, status: completed)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: fosbretabulin, carboplatin, paclitaxel, bevacizumab
SMILES: COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed Stage IIIB NSCLC with malignant pleural effusion, or Stage IV
             disease

          -  Measurable disease on CT scan (by the Response Evaluation Criteria in Solid Tumors
             [RECIST] criteria)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 (which
             means able to independently care for self and to perform light work) .

          -  Adequate blood counts

          -  Adequate liver and kidney function

          -  Subjects or their legal representatives must be able to read, understand and provide
             written informed consent to participate in the trial.

        Exclusion Criteria:

          -  Predominant Squamous Cell NSCLC histology.

          -  History of treatment for NSCLC with chemotherapy, biological therapy, immunotherapy
             (surgery or radiation therapy are accepted)

          -  Brain (CNS) metastasis by head CT scan or MRI

          -  Subjects with history of prior malignancy except for curatively treated basal cell
             carcinoma of the skin; cervical intra-epithelial neoplasia; or localized prostate
             cancer with a current prostate specific antigen (PSA) of < 4.0 mg/dL. Subjects with
             other curatively treated malignancies who have no evidence of metastatic disease and
             >2 year disease free interval may be entered after discussion with the Medical
             Monitor.

          -  History of bleeding disorders, particularly coughing up ≥ ½ teaspoon bright red blood
             during the last 3 months

          -  Certain cardiac disorders such as recent myocardial infarction (MI), severe congestive
             heart failure, certain types of abnormal cardiac rhythm

          -  Uncontrolled high blood pressure despite medications

          -  Uncontrolled, clinically significant active infection.

          -  Known HIV

          -  Known hypersensitivity to any of the components of CA4P, paclitaxel, carboplatin,
             bevacizumab, or radiologic contrast dyes.

        Details of the above and additional inclusion and exclusion criteria can be discussed with
        an investigator.
Clinical trial NCT00461123 (phase 2, status: completed)
Conditions: prostatic hypertrophy, benign
ICD codes: J35.3, J35.1, J35.2, N28.81, N62, N85.2, J34.3
Drugs: vardenafil (levitra, bay38-9456), placebo
SMILES: CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men with benign prostate hypertrophy requiring surgical treatment

          -  Age up to 80 years

          -  Documented, dated, written Informed Consent

          -  Anesthesiologists agreement with swallowing 1 tablet one hour prior surgery

        Exclusion Criteria:

          -  Any unstable medical, psychiatric, or substance abuse disorder

          -  History of previous prostatectomy

          -  Patients suspect of prostate cancer

          -  Hereditary degenerative retinal disorder

          -  History of previous Non-arteric Anterior Ischemic Optic Neuropathy (NAION) episode or
             unilateral vision impairment

          -  Any cardiovascular condition

          -  History of myocardial infarction, stroke or life-threatening arrhythmia within the
             prior 6 months

          -  Uncontrolled atrial fibrillation/flutter at screening

          -  Severe chronic or acute liver disease

          -  Chronic hematological disease which may lead to priapism

          -  Bleeding disorder

          -  Significant active peptic ulceration

          -  Resting hypotension

          -  History of positive test for Hepatitis B surface antigen or Hepatitis C

          -  Symptomatic postural hypotension within 6 months of Visit 1

          -  Patients who subjectively or in the opinion of the investigator did not tolerate the
             initial dose of study medication well

          -  Subjects who are taking nitrates or nitric oxide donors

          -  Subjects who are taking androgens or anti-androgens

          -  Subjects who are taking potent inhibitors of cytochrome P4503A4

          -  Subjects who have received any investigational drug within 30 days of Visit 1

          -  Using of alpha-blockers during two days prior to first dosing of study medication and
             after ablation of prostate

          -  Use of inhibitors of 5-alpha reductase after ablation of prostate

          -  Subjects with serum creatinine clearance <30.0 mL/min

          -  Elevation of Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >3
             times the upper limit of normal

          -  Subjects with known hypersensitivity to Vardenafil

          -  Subjects who are illiterate or unable to understand subject diaries

          -  Subjects who would be non-compliant with the study visit schedule
Clinical trial NCT00061308 (phase 2, status: completed)
Conditions: peritoneal cancer, ovarian cancer, neoplasms, ovarian, fallopian tube cancer
ICD codes: K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02
Drugs: topotecan, gemcitabine
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Have had one prior platinum-based chemotherapy regimen for the treatment of primary
             disease.

          -  At least 4 weeks since last surgery or radiation therapy.

          -  Must have had a treatment-free interval of greater than 6 months following response to
             platinum.

          -  ECOG performance status of 0,1, or 2.

        Exclusion Criteria:

          -  Women of child-bearing potential that do not practice adequate contraception.

          -  Pregnant or lactating.

          -  Received more than one primary chemotherapy regimen.

          -  Concomitant or previous malignancies with the exception of adequately treated basal
             cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or
             other cancer from which the patient has been disease free for 5 years.

          -  Active uncontrolled infection requiring antibiotics.

          -  Concurrent severe medical problems unrelated to the malignancy which would limit full
             compliance with the study.

          -  Received radiation to more than 10% of bone.

          -  Prior treatment with topotecan or gemcitabine.

          -  Hypersensitivity to camptothecin or nucleoside analogues.

          -  Use of an investigational agent within 30 days.
Clinical trial NCT01173887 (phase 2, status: completed)
Conditions: adult t-cell leukemia-lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: vcap/amp/vecp(mlsg15)
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who have been positive for serum anti-human T-cell lymphotropic virus type I
             antibody

          -  Subjects with hematologically or pathohistologically confirmed as peripheral lymphoid
             tumor which surface antigen analysis has identified to be of T-cell origin

          -  Subjects who have been classified into acute subtype, the lymphoma subtype or chronic
             subtype with poor prognostic factors

          -  Subjects who have been positive for CCR4 by CCR4 expression analysis

          -  Subjects who have never been treated for adult T-cell leukemia-lymphoma

          -  Subjects who have presented enlarged lymph nodes, tumor nodules in extranodal organs,
             abnormal lymphocytes in peripheral blood or cutaneous lesions

          -  Subjects with a performance status of 0 to 2

          -  Subjects who have been negative for HBs antigen and anti-HCV antibody

          -  Subjects who have given written voluntary informed consent to participate in the study

        Exclusion Criteria:

          -  Subjects who are scheduled for transplant therapy such as hematopoietic stem-cell
             transplantation

          -  Subjects who had myocardial infarction within 12 months before study enrollment or who
             have cardiac disease that may worsen during treatment with doxorubicin

          -  Subjects who have been positive for anti-HIV antibody

          -  Subjects with active multiple cancer

          -  Subjects with a history of allergic reactions to therapeutic antibodies

          -  Subjects who require emergency radiotherapy for treating the symptoms caused by bulky
             masses or who may require such radiotherapy after the start of the study

          -  Subjects who are pregnant, lactating or of childbearing potential, or who are planning
             to have children
Clinical trial NCT01418222 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: 5-fu, folfox regimen, placebo, bevacizumab [avastin], leucovorin, onartuzumab [metmab]
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >/= 18 years of age

          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in
             patients with metastatic (Stage IV) disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Measurable disease by RECIST criteria

          -  Adequate organ system function, as defined by protocol

        Exclusion Criteria:

          -  Prior systemic or radiation therapy for metastatic colorectal cancer

          -  Adjuvant chemotherapy (and/or chemoradiation) for colorectal cancer within 12 months
             prior to date of diagnosis of metastatic disease

          -  Previously untreated brain metastases

          -  History of hypersensitivity to active or inactive excipients of any component of
             treatment, or known dipyrimidine dehydrogenase deficiency

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)

          -  History of hematemesis or hemoptysis </= 1 months prior to study enrollment

          -  Significant cardiovascular disease or disorder

          -  History of abdominal fistula or gastrointestinal perforation </= 6 months prior to Day
             1

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  Other active cancers or history of treatment for invasive cancer within the last 5
             years, except for non-melanoma skin cancer
Clinical trial NCT00100945 (phase 2, status: completed)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the esophagus or
             gastroesophageal junction

               -  Locally advanced disease

                    -  T3 or T4 tumor with no lymph node involvement OR any T stage with local
                       lymph node involvement

                         -  Celiac node involvement allowed

                         -  No supraclavicular lymph node involvement

          -  Received potentially curative chemotherapy, radiotherapy, and/or surgery within the
             past 1-3 months

               -  Patients who received adjuvant chemotherapy or chemoradiotherapy after surgery
                  are eligible provided last treatment was administered within the past 3 months

          -  No evidence of residual tumor or metastatic disease after undergoing potentially
             curative therapy

               -  No positive margins at the time of prior surgery

               -  No measurable or evaluable disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 2.0 mg/dL

        Renal

          -  Creatinine ≤ 2 times upper limit of normal

        Cardiovascular

          -  No New York Heart Association class III or IV heart disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Able to swallow study drug

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or noninvasive carcinoma

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

        Surgery

          -  See Disease Characteristics

        Other

          -  No prior gefitinib

          -  No concurrent CYP3A4 inducing agents, including any of the following:

               -  Carbamazepine

               -  Oxcarbazepine

               -  Modafinil

               -  Ethosuximide

               -  Griseofulvin

               -  Nafcillin

               -  Phenobarbital

               -  Phenylbutazone

               -  Phenytoin

               -  Primidone

               -  Rifampin

               -  Hypericum perforatum (St. John's wort)

               -  Sulfinpyrazone

          -  No concurrent antacids 4 hours before or after study drug administration